Ziarco Launches with $27M Series A, Assets from Pfizer

LONDON – Four Pfizer Inc. scientists and executives have formed a new company specializing in inflammatory and allergic diseases around assets deemed surplus to requirements following the closure of the U.S. pharma company's UK R&D center in Sandwich, Kent.